Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer

Cancer Biology and Therapy

Volumn 15, Issue 8, 2014, Pages 1061-1067

  Reusser, Nicole M ^a,b   Dalton, Heather J ^b   Pradeep, Sunila ^b   Gonzalez Villasana, Vianey ^b   Jennings, Nicholas B ^b   Vasquez, Hernan G ^c   Wen, Yunfei ^b   Rupaimoole, Rajesh ^b   Nagaraja, Archana S ^b   Gharpure, Kshipra ^b   Miyake, Takahito ^b   Huang, Jie ^b   Hu, Wei ^b   Lopez Berestein, Gabriel ^a,b   Sood, Anil K ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Anti angiogenesis; Bisphosphonate; Clodronate; Ovarian cancer; Tumor angiogenesis; Tumor microenvironment; Tumor associated macrophages

Indexed keywords

CLODRONIC ACID; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 6; INTERLEUKIN 8; LIPOSOME; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; BONE DENSITY CONSERVATION AGENT; CYTOKINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY DENSITY; CAPILLARY TUBE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; OVARY TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL MOTION; DRUG EFFECTS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CLODRONIC ACID; CYTOKINES; ENDOTHELIAL CELLS; FEMALE; HUMANS; MACROPHAGES; MICE, INBRED C57BL; OVARIAN NEOPLASMS;

EID: 84905487210     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.29184     Document Type: Article

References (18)

1. Hall M, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, Perren T, Rustin G, Kaye S. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 2013; 108:250-8; PMID:23385789; http://dx.doi.org/10.1038/ bjc.2012.541
2. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307; PMID:21593862; http://dx.doi.org/10. 1038/nature10144
3. Través PG, Luque A, Hortelano S. Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm 2012; 2012:568783; PMID:23316105; http://dx.doi.org/10.1155/2012/568783
4. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011; 121:1969-73; PMID:21490397; http://dx.doi.org/10.1172/JCI44562
5. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67; PMID:22039576; http://dx.doi.org/10. 1158/2159-8274.CD-10-0028
6. Russell RG. Bisphosphonates: the first 40 years. Bone 2011; 49:2-19; PMID:21555003; http://dx.doi.org/10.1016/j.bone.2011.04.022
7. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjällman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006; 95:272-81; PMID:16832418; http://dx.doi.org/10. 1038/sj.bjc.6603240
8. Baer C, Squadrito ML, Iruela-Arispe ML, De Palma M. Reciprocal interactions between endothelial cells and macrophages in angiogenic vascular niches. Exp Cell Res 2013; 319:1626-34; PMID:23542777; http://dx.doi.org/10. 1016/j.yexcr.2013.03.026
9. Giger EV, Castagner B, Leroux JC. Biomedical applications of bisphosphonates. J Control Release 2013; 167:175-88; PMID:23395668; http://dx.doi.org/10.1016/j.jconrel.2013.01.032
10. Ribatti D, Maruotti N, Nico B, Longo V, Mangieri D, Vacca A, Cantatore FP. Clodronate inhibits angiogenesis in vitro and in vivo. Oncol Rep 2008; 19:1109-12; PMID:18425365
11. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res 2007; 100:782-94; PMID:17395884; http://dx.doi.org/10. 1161/01.RES.0000259593.07661.1e
12. Hafeman SD, Varland D, Dow SW. Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells. Vet Comp Oncol 2012; 10:44-56; PMID:22236140; http://dx.doi.org/10.1111/ j.1476-5829.2011.00274.x
13. Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K, Pylkkänen L, Pecherstorfer M, Aapro MS. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol 2007; 64:198-207; PMID:17855108; http://dx.doi.org/10.1016/j.critrevonc.2007.07.005
14. Winter MC, Coleman RE. Bisphosphonates in the adjuvant treatment of breast cancer. Clin Oncol (R Coll Radiol) 2013; 25:135-45; PMID:23207072; http://dx.doi.org/10.1016/j.clon.2012.10.010
15. Zhu J, Zheng Y, Zhou Z. Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis. Eur J Cancer 2013; 49:2086-92; PMID:23452992; http://dx.doi.org/10.1016/j.ejca.2013.01.021
16. Saad F, Colombel M. Management of castrationresistant prostate cancer: bisphosphonates and emerging therapies. Expert Rev Anticancer Ther 2010; 10:1991-2002; PMID:21110764; http://dx.doi.org/10.1586/era.10.191
17. Rodrigues P, Hering FO, Meller A. Adjuvant effect of IV clodronate on the delay of bone metastasis in high-risk prostate cancer patients: a prospective study. Cancer Res Treat 2011; 43:231-5; PMID:22247708; http://dx.doi.org/10. 4143/crt.2011.43.4.231
18. Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S, Pignata S. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther 2010; 10:47-60; PMID:20014885; http://dx.doi.org/10.1586/era.09.167